Indian Journal of Critical Care Case Report

Register      Login

VOLUME 3 , ISSUE 1 ( January-February, 2024 ) > List of Articles

CLINICAL CASE DISCUSSION

Thrombocytopenia in the Critically Ill: An Animal with Several Heads

Raghuram N Thiriveedhi, Ramesh Venkataraman, Sristi Patodia

Keywords : Fever, Myalgia, Systemic hypertension, Thrombocytopenia

Citation Information : Thiriveedhi RN, Venkataraman R, Patodia S. Thrombocytopenia in the Critically Ill: An Animal with Several Heads. 2024; 3 (1):1-5.

DOI: 10.5005/jp-journals-11006-0089

License: CC BY-NC 4.0

Published Online: 30-12-2023

Copyright Statement:  Copyright © 2024; The Author(s).


Abstract

A 59-year-old male with a history of systemic hypertension and fever presented as an interesting patient with thrombocytopenia. While fever with thrombocytopenia is a common presentation, this patient's course in the hospital took multiple twists and turns, taking us through a tutorial in thrombocytopenia.


HTML PDF Share
  1. Thachil J, Warkentin TE. How do we approach thrombocytopenia in critically ill patients? Br J Haematol 2017;177(1):27–38. DOI: 10.1111/bjh.14482
  2. Krzych ŁJ, Nowacka E, Knapik P. Heparin-induced thrombocytopenia. Anaesthesiol Intensive Ther 2015;47(1):63–76. DOI: 10.5603/AIT.2015.0006
  3. Lo GK, Juhl D, Warkentin TE, et al. Evaluation of pretest clinical score (4 T’s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006;4(4):759–765. DOI: 10.1111/j.1538-7836.2006.01787.x
  4. Bakchoul T, Zöllner H, Greinacher A. Current insights into the laboratory diagnosis of HIT. Int J Lab Hematol 2014;36(3):296–305. DOI: 10.1111/ijlh.12236
  5. Hogan M, Berger JS. Heparin-induced thrombocytopenia (HIT): Review of incidence, diagnosis, and management. Vasc Med 2020;25(2):160–173. DOI: 10.1177/1358863X19898253
  6. Pravinkumar E, Webster NR. HIT/HITT and alternative anticoagulation: current concepts. Br J Anaesth 2003;90(5):676–685. DOI: 10.1093/bja/aeg063
  7. Warkentin TE, Pai M, Linkins LA. Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review. Blood 2017;130(9):1104–1113. DOI: 10.1182/blood-2017-04-778993
  8. Pollak U. Heparin-induced thrombocytopenia complicating extracorporeal membrane oxygenation support: review of the literature and alternative anticoagulants. J Thromb Haemost 2019;17(10):1608–1622. DOI: 10.1111/jth.14575
  9. Refaai MA, Chuang C, Menegus M, et al. Outcomes after platelet transfusion in patients with heparin-induced thrombocytopenia. J Thromb Haemost 2010;8(6):1419–1421. DOI: 10.1111/j.1538-7836.2010.03861.x
  10. Hopkins CK, Goldfinger D. Platelet transfusions in heparin-induced thrombocytopenia: a report of four cases and review of the literature. Transfusion 2008;48(10):2128–2132. DOI: 10.1111/j.1537-2995.2008.01822.x
  11. Padmanabhan A, Jones CG, Pechauer SM, et al. IVIg for treatment of severe refractory heparin-induced thrombocytopenia. Chest 2017;152(3):478–485. DOI: 10.1016/j.chest.2017.03.050
  12. Warkentin TE, Sheppard JA, Chu FV, et al. Plasma exchange to remove HIT antibodies: dissociation between enzyme-immunoassay and platelet activation test reactivities. Blood 2015;125(1):195–198. DOI: 10.1182/blood-2014-07-590844
  13. Batra A, Singh R, Singal A, et al. Rituximab in the treatment of refractory heparin induced thrombocytopenia. Blood 2022;140(Suppl 1):11339–11341. DOI: 10.1182/blood-2022-170542
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.